Breast Cancer Research Review Issue 82
In this issue:
An individualised mRNA-based neoantigen vaccine in TNBC
Survival with complementary/alternative medicine in breast cancer
Supplemental breast MRI according to risk/tissue density
An AI model to estimate Oncotype DX recurrence scores
TBCRC 035: reduced-dose palbociclib + endocrine therapy in HR+/HER2– breast cancer
Brain MRI screening in HER2+ breast cancer/TNBC
VIKTORIA-1: gedatolisib + fulvestrant ± palbociclib in HR+/HER2−/PIK3CA wild-type breast cancer
Survival with/without risk-reducing mastectomy in BRCA1/2 carriers
SOLTI-1716 TATEN: pembrolizumab + paclitaxel in HR+/HER2− breast cancer
classified as HER2-enriched or basal-like EMBER-3: updated OS analysis of imlunestrant ± abemaciclib in HR+/HER2− breast cancer
Expert contributor
Dr Hilary Martin
Dr Hilary Martin, is a medical oncologist at Fiona Stanley Hospital Perth subspecialising in breast cancer. Her initial oncology training was undertaken in South Australia. She subsequently worked as a breast unit fellow at the Royal Marsden Hospital, London, and also as a clinical fellow at Royal Perth Hospital. She has a Masters of Public […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.